Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Aug 9, 2022 · 10-Q · 40 days after period end · 0000950170-22-016059
| Metric | Q1 2022 | Q1 2020 | Q1 2019 |
|---|---|---|---|
| Revenue | $9.12M | $11.55M | $13.17M |
| Net Income | -$61.22M | -$19.52M | -$10.13M |
| EPS Diluted | -$0.82 | -$0.74 | -$4.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end
